Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why BioMarin Pharmaceutical Leapt 10.2% in November

By Maxx Chatsko - Dec 4, 2019 at 1:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The business reported a handful of positive developments.

What happened

Shares of BioMarin Pharmaceutical ( BMRN 0.44% ) rose more than 10% last month, according to data from S&P Global Market Intelligence. The rare-disease specialist reported promising results from an ongoing phase 2 trial of an important drug candidate, held its annual research and development (R&D) day for investors, and submitted a marketing application for a gene therapy in the European Union. 

Despite the monthly gains, shares of BioMarin Pharmaceutical have lost nearly 6% of their value since the beginning of 2019. It was much worse -- the pharma stock was down 24% on the same basis at the end of September -- but shares have rallied in recent months. Can it finish the year strong?

A rising column chart with the last and tallest column represented by a red arrow on a springboard.

Image source: Getty Images.

So what

It was a busy month for BioMarin Pharmaceutical. The company reported that children with achondroplasia, the rare disease more commonly referred to as dwarfism, achieved statistically significant gains in height versus what might be expected when treated with vosoritide. The treated individuals gained an additional 9 centimeters (3.5 inches) in height compared with untreated individuals, using a database of achondroplasia patients, in 54 months spanning a phase 2 and phase 3 trial. 

That was the highlight of the R&D Day, but investors have additional developments to look forward to. The business expects to complete regulatory submissions in the United States and Europe before the end of 2019 for its gene therapy (valoctocogene roxaparvovec) targeting hemophilia A. In fact, it submitted the marketing application in the European Union on Nov. 21.

BioMarin Pharmaceutical also announced that it has selected its next two pipeline candidates, including a third gene therapy drug candidate, and that it's exploring the potential to develop vosoritide in dominantly inherited short stature applications. The business told investors it can achieve breakeven or better net income in 2020 -- if the gene therapy in hemophilia A launches in the second half of next year.

Now what

The rare-disease specialist is now valued at over $14 billion. While the business won't be profitable in 2019, it did achieve operating income in the third quarter of 2019. Depending on the growth trajectory of currently approved products and regulatory outcomes in the next six months or so, BioMarin Pharmaceutical could finally become a profitable biotech stock in 2020 or shortly thereafter. Achieving that milestone will greatly de-risk future development and expansion activities, especially in the ultra-expensive gene therapy space.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioMarin Pharmaceutical Inc. Stock Quote
BioMarin Pharmaceutical Inc.
BMRN
$84.88 (0.44%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
635%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.